Bioavailability of nifedipine: A comparison between two preparations
β Scribed by E. Zylber-Katz; G. Koren; L. Granit; M. Levy
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 297 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
In a random crossβover study, eight healthy volunteers received single 10 mg doses of either nifedipine capsule (Adalat, Bayer) or nifedipine tablets (Taro) after an overnight fast. The areas under the serum concentration time curves were not significantly different (AUC^0β β^ 319Β·8 Β± 28Β·0 (SEM) ng ml^β1^ h^β1^ for capsules, 260Β·8 Β± 15Β·3 ng ml^β1^ h^β1^ for tablets). The peak serum levels and the time of their occurrence were 162Β·4 Β± 23Β·4 ng ml^β1^ at 30 min for capsules and 43Β·0 Β± 3Β·0 ng ml^β1^ at 1β2 h for tablets, indicating that the absorption of nifedipine from the capsule is faster than from the tablet form. Clinical symptoms of vasodilation corresponded with the nifedipine peak levels. We conclude that although the bioavailability in general of the two preparations is similar, the therapeutic equivalence may differ. Depending on the therapeutic indication each preparation may have its merits.
π SIMILAR VOLUMES
The bioavailability of two slow release preparations of disopyramide has been compared in a randomized cross-over trial of Rythmodan L.A. 250 mg b.d. and Dirytmin Durettes 300 mg b.d., given to 10 healthy volunteers. The plasma concentrations of disopyramide were measured on the 5th day of each trea
Plasma concentrations of two phenytoin products (a conventional phenytoin acid preparation and a microcrystalline form of phenytoin acid) were studied after single dose administration and during steady-state conditions in four healthy male volunteers. Relative bioavailability for the conventional ta